First in Human Study for PF-06667272

Study Overview
=================
Brief Summary
-----------------
The current study is the first clinical trial proposed with PF-06667272. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single ascending doses of PF-06667272 under fed and fasted conditions, in healthy adult subjects.

Official Title
-----------------
A Phase 1, Randomized, Double-blind (Sponsor-open), Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06667272 Under Fed And Fasted Conditions, In Healthy Adult Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: PF-06667272
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy males and female of non-childbearing potential; Body Mass Index 17.5-30.5 kg/m2; Body weight >50 kg; Exclusion Criteria: Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cohort 1_Period 1_Active<br>Single ascending dose of PF-06667272 | Drug: PF-06667272<br>* Single ascending dose of PF-06667272<br>|
| Placebo Comparator: Cohort 1_Period 1_Placebo<br>Single dose of placebo | Other: Placebo<br>* Single dose of placebo<br>|
| Experimental: Cohort 1_Period 2_Active<br>Single ascending dose of PF-06667272 | Drug: PF-06667272<br>* Single ascending dose of PF-06667272<br>|
| Placebo Comparator: Cohort 1_Period 2_Placebo<br>Single dose of placebo | Other: Placebo<br>* Single dose of placebo<br>|
| Experimental: Cohort 1_Period 3_Active<br>Single ascending dose of PF-06667272 | Drug: PF-06667272<br>* Single ascending dose of PF-06667272<br>|
| Placebo Comparator: Cohort 1_Period 3_Placebo<br>Single dose of placebo | Other: Placebo<br>* Single dose of placebo<br>|
| Experimental: Cohrot 1_Period 4_Active<br>Single ascending dose of PF-06667272 | Drug: PF-06667272<br>* Single ascending dose of PF-06667272<br>|
| Placebo Comparator: Cohort 1_Period 4_Placebo<br>Single dose of placebo | Other: Placebo<br>* Single dose of placebo<br>|
| Experimental: Cohort 2_Period 1_Active<br>Single ascending dose of PF-06667272 | Drug: PF-06667272<br>* Single ascending dose of PF-06667272<br>|
| Placebo Comparator: Cohort 2_Period 1_Placebo<br>Single dose of placebo | Other: Placebo<br>* Single dose of placebo<br>|
| Experimental: Cohort 2_Period 2_Active<br>Single ascending dose of PF-06667272 | Drug: PF-06667272<br>* Single ascending dose of PF-06667272<br>|
| Placebo Comparator: Cohort 2_Period 2_Placebo<br>Single dose of placebo | Other: Placebo<br>* Single dose of placebo<br>|
| Experimental: Cohort 2_Period 3_Active<br>Single ascending dose of PF-06667272 | Drug: PF-06667272<br>* Single ascending dose of PF-06667272<br>|
| Placebo Comparator: Cohort 2_Period 3_Placebo<br>Single dose of placebo | Other: Placebo<br>* Single dose of placebo<br>|
| Experimental: Cohort 2_Period 4_Active<br>Single ascending dose of PF-06667272 | Drug: PF-06667272<br>* Single ascending dose of PF-06667272<br>|
| Placebo Comparator: Cohort 2_Period 4_Placebo<br>Single dose of placebo | Other: Placebo<br>* Single dose of placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Subjects With Treatment Emergent Treatment-Related Adverse Events (AEs) or other safety concerns | Assessment by adverse event monitoring, 12 lead ECGs, telemetry, vital signs and clinical safety laboratory measurements. Treatment-related AE was any untoward medical occurrence attributed to study drug in a subject who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Drug was assessed by the investigator (Yes/No). Subjects with multiple occurrences of an AE within a category were counted once within the category. | Baseline (Day 1, hour 0) up to 28 days after last dose of study medication | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06667272 and PF-06818073 | Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) | 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post dose | 
| Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0- infinity)] for PF-06667272 and PF-06818073 (as permitted) | AUC (0-infinity)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-infinity). It is obtained from AUC (0-t) plus AUC (t-infinity). | 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post dose | 
| Maximum Observed Plasma Concentration (Cmax) for PF-06667272 and PF-06818073 | Maximum Observed Plasma Concentration (Cmax) | 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post dose | 
| Time to Reach Maximum Observed Concentration for PF-06667272 and PF-06818073 | Time to Reach Maximum Observed Plasma Concentration (Tmax) | 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post dose | 
| Plasma Decay Half-Life (t1/2) for PF-06667272 and PF-06818073 | Plasma Decay Half-Life (t1/2) | 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post dose | 
| Apparent Total Body Clearance (CL/F) for PF-06667272 | Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after apparent total body clearance is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. | 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post dose | 
| Apparent Volume of Distribution (Vz/F) for PF-06667272 | Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed. | 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post dose |